<DOC>
	<DOCNO>NCT00252330</DOCNO>
	<brief_summary>To evaluate efficacy fix dose SR58611A ( 350 mg q12 ) compare placebo patient MajorDepressive Disorder ( MDD ) use escitalopram ( 10 mgqd ) positive control . In addition , tolerability safety SR58611A patient MDD evaluate .</brief_summary>
	<brief_title>Efficacy Safety SR58611A Patients With Major Depressive Disorder</brief_title>
	<detailed_description>To evaluate efficacy fix dose SR58611A ( 350 mg q12 ) compare placebo patient MajorDepressive Disorder ( MDD ) use escitalopram ( 10 mgqd ) positive control . In addition , tolerability safety SR58611A patient MDD evaluate . The present study 8-week , double-blind , placebo- escitalopram-controlled , randomize , parallel-group study . A 1-week , placebo , single-blind period precedes 8-week randomized treatment period optional 18-week , double-blind extension period follow randomize treatment period . A Safety Follow Visit schedule 1 week acute extension period , early termination . Escitalopram , selective serotonin reuptake inhibitor ( SSRI ) , approve treatment MDD , chosen positive control agent study . The dose 10 mg within approve dose range need dose adjustment elderly patient . This trial design formally compare efficacy , safety , tolerability SR58611A placebo . Escitalopram use positive control .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<criteria>Main inclusion criterion : 1 . Outpatients , 18 year older . 2 . Major Depressive Disorder ( MDD ) recurrentMajor Depressive Episode ( MDE ) accord DSMIVTR criterion 3 . Duration current episode least 6 weeksunless severity symptom justifies short duration . 4 . Patients treat hospitalized aprevious episode , previous episode requiredantidepressant treatment ( ) recommend doselevel continuous total duration least 2months . Main exclusion criterion : 1 . Patients immediate risk suicidal behavior 2 . Patients MDE psychotic feature , catatonic feature , seasonal pattern postpartum onset 3 . The duration current depressive episode great 2 year 4 . Patients whose current depressive episode secondary general medical condition 5 . Patients lifetime history ( 1 ) bipolar disorder , ( 2 ) psychotic disorder , ( 3 ) antisocial personality disorder 6 . Patients receive nonpharmacologic , somatic treatment psychiatric disease 7 . Patients initiated , stop , change frequency nature psychotherapy within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>major depressive disorder</keyword>
	<keyword>depression</keyword>
	<keyword>major depressive episode</keyword>
	<keyword>antidepressive agent</keyword>
</DOC>